Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.

13. listopadu 2026 aktualizováno: Beijing Baheal Wisart Medical Research Co., Ltd

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YY524051 Tablets in Healthy Participants

This is a Phase 1 study to evaluate the safety, tolerability, and how the body processes an investigational drug called YY524051 tablets in healthy participants.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

This is a single-center Phase 1, randomized, double-blind, placebo controlled, first-in-human (FIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of an investigational drug called YY524051 tablets in healthy adult participants.

The study is divided into two parts:

Single Ascending Dose (SAD) part: Participants will receive a single dose of the drug to see how the body handles it and to determine a safe dose level. A staggered dosing schedule will be used, where a few "sentinel" participants will be dosed first to ensure safety before the rest of the cohort receives the drug. A food-effect (FE) assessment will be nested at a selected dose level after fasting dosing during escalation, and a clinical QT/QTc (CQTc) assessment will be embedded within selected SAD cohorts.

Multiple Ascending Dose (MAD) part: Participants will take the drug repeatedly over several days to assess accumulation and steady-state in the body and to further evaluate its safety.

Participants will be randomly assigned to receive either YY524051 tablets or a placebo (placebo tablet containing no active ingredient). The study is "double-blind," meaning neither the participants nor investigators will know who is receiving the real drug.

The information gathered from this study will help researchers understand the best way to give this drug, characterize its PK profile, and determine a safe dose for future studies in patients.

Typ studie

Intervenční

Zápis (Odhadovaný)

78

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Beijing, Čína
        • Peking University Third Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 45 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

Participants must meet ALL of the following criteria to be eligible for enrollment:

  • Healthy participants, male or female (the ratio of males to females will be kept as balanced as possible).
  • Age between 18 and 45 years (inclusive). Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) between 19.0 and 28.0 kg/m² (inclusive). BMI = weight (kg) / height² (m²).
  • Able to understand the informed consent form, and voluntarily participate and sign the informed consent form.

Exclusion Criteria:

Participants who meet ANY of the following criteria will be excluded from the study:

  • History of drug allergy, or known allergy to the investigational product or any of its excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, povidone, magnesium stearate, film coating premix (gastric-soluble), sodium stearyl fumarate, lactose);
  • History of or current clinically significant diseases in the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic systems, as determined by the investigator;
  • History of drug addiction; history of alcohol abuse within 6 months prior to screening (defined as consuming more than 14 standard units of alcohol per week [1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine]); average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening; positive urine drug screen or positive alcohol breath test at screening; or inability to comply with the prohibition of smoking/alcohol during the study period;
  • History of cardiovascular or cerebrovascular surgery; history of any surgery affecting drug absorption, distribution, metabolism, or excretion; severe trauma or surgery within 6 months prior to screening; or planned surgery during the study period;
  • Positive results for any of the following: Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCVAb), Treponema pallidum particle agglutination (TPPA), or Human Immunodeficiency Virus (HIV) antibody;
  • Positive pregnancy test for female participants;
  • Breastfeeding female participants; female participants who refuse to use effective non-pharmacological contraceptive measures (e.g., abstinence, intrauterine device) or have egg donation plans from signing the informed consent until 90 days after the last dose; male participants who refuse to commit to no reproductive or sperm donation plans or refuse to use effective physical contraceptive measures, or have sperm donation plans from signing the informed consent until 90 days after the last dose;
  • Abnormalities in physical examination, laboratory tests, vital signs, echocardiography, abdominal ultrasound, or chest X-ray that are clinically significant as determined by the investigator and may affect the evaluation of study endpoints;
  • Blood pressure ≥ 140/90 mmHg or < 90/50 mmHg; heart rate < 50 beats/min or > 100 beats/min;
  • Clinically significant abnormalities on 12-lead electrocardiogram (ECG) as determined by the investigator, including: Prolonged QT interval: QTcF > 450 msec (males) or > 470 msec (females); PR interval > 200 msec; QRS interval > 120 msec;
  • Consumption of excessive tea, coffee, or caffeine-containing beverages (≥ 8 cups per day, 1 cup = 250 mL) daily within 3 months prior to screening; or habitual consumption of any xanthine-rich beverages or foods (e.g., caffeine, theophylline, theobromine) or fruits/foods affecting metabolic enzymes (e.g., grapefruit, pomelo, starfruit, mango) that cannot be abstained from during the study period;
  • Special dietary requirements or inability to comply with a standardized diet;
  • Difficulty swallowing tablets;
  • Inability to tolerate venipuncture, history of hemophobia/needle phobia, or poor vascular conditions making blood collection difficult;
  • Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days prior to screening; or use of any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within 2 weeks (or 5 half-lives, whichever is longer) prior to screening;
  • Participation in any clinical trial within 3 months prior to screening; or still within 5 half-lives of an investigational drug from a previous clinical trial at screening;
  • History of blood donation or significant blood loss (≥ 400 mL) within 3 months prior to screening or between screening and first dose; history of blood transfusion within 3 months; or plans to donate blood during the study period;
  • Poor compliance or any other conditions that make the participant unsuitable for the study as judged by the investigator.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Placebo

Matching placebo tablets will be administered orally to participants in the control groups. In the SAD phase (initially planned up to 5 cohorts), a single dose will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), placebo will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC)

Matching placebo.

Experimentální: YY524051 tablets

YY524051 tablets will be administered orally to participants in the treatment groups. In the SAD phase (initially planned up to 5 cohorts), single ascending doses will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), multiple ascending doses will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts and dose levels may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC).

YY524051 tablets administered orally

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs)
Časové okno: SAD: Day1 to Day 8 MAD: Day1 to Day 14

Safety and Tolerability as assessed by AEs and SAEs

SAD: Day1 to Day 8 MAD: Day1 to Day 14

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Tmax
Časové okno: Pre-dose to 48 hours post-dose

Peak time: The time required to reach peak concentration after administration

Pre-dose to 48 hours post-dose
Cmax
Časové okno: Pre-dose to 48 hours post-dose

Peak concentration: The highest blood concentration after administration

Pre-dose to 48 hours post-dose
AUC
Časové okno: Pre-dose to 48 hours post-dose

Area under the drug time curve: The area surrounded by the blood concentration curve to the time axis.

Pre-dose to 48 hours post-dose
t1/2
Časové okno: Pre-dose to 48 hours post-dose

Terminal elimination half-life: The time required for the terminal phase blood concentration to decrease by half

Pre-dose to 48 hours post-dose

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. prosince 2026

Primární dokončení (Odhadovaný)

1. prosince 2027

Dokončení studie (Odhadovaný)

1. prosince 2027

Termíny zápisu do studia

První předloženo

13. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

13. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • YY524051-I-01
  • CTR20264102 (Jiný identifikátor: CDE,NMPA)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .